US Kidney Research Corporation was born from a series of events that occurred before its inception. It began with a man named Charles Edward Jennings, a scientist, engineer and inventor with over 50 patents, including US Patent 7083653, a prototype of an implantable artificial kidney. For many reasons, it sat unfinished for several years. Roland Ludlow, whom later became his son in law, encourage Mr. jennings to revive his project since both had lost close family members to renal disease. In 2013, together they began a company called the Implantable Artificial Kidney Corporation (IAKC) and were able to raise 500k starting capital to implement further research.
Then an unfortunate and untimely event occurred. Mr. Jennings had a stroke and was unable to recover. He passed away in February 2014 just 7 months after IAKC’s inception. Not long after his passing Mr. Ludlow received a phone call from Dr. Ira Kurtz, Chief of the Division of Nephrology at the University of California, Los Angeles. (UCLA). He had been following IAKC’s progress online, and was aware of Mr. Jennings passing. He wanted to help and took on the role of Medical/Science Adviser for IAKC. Several months into the project, Dr. Kurtz presented an idea to Mr. Ludlow that he believed had better promise than the methodology they were pursuing. He wanted to start a completely new design using a methodology that already existed called electrodeionization, but had never been used to create an artificial kidney.
The idea Dr. Kurtz had was brilliant and so novel that Mr. Ludlow felt that the research merited complete secrecy. He decided along with his investors to shut down IAKC, and founded Curion Research Corporation, which remained stealth for the next 3 years. At the beginning of this pursuit, Curion signed a subcontracting agreement with the University of Arkansas, the only US University that had knowledgeable researchers in the field of electrodeionization, a lab and equipment to perform specific experiments in that field, and a machine shop to build any needed parts. They have been involved ever since.
Curion has been in existence for nearly 4 years now, and unveiled their steath status after their patent application was published online by the USPTO and became public knowledge in March 2018. Curion Research Corporation recently changed their name toUS Kidney Research Corporation (USKRC).
Over the last 4 years Curion Research Corporation (USKRC) has achieved enormous success. They have developed the first technology ever to use electrodeionization as a methodology to develop an artificial kidney. This is the first blood purification technology that doesn’t use water, dialysate concentrate solutions, or a dialyzer, the very things dialysis depends on. The technology will offer real time data providing more precise treatments resulting in better patient outcomes. The same technology can be used to make a standalone machine, a wearable artificial kidney, and an implantable kidney.
Curion was announced a winner of the KidneyX Redesign Dialysis Contest presented by the US Dept. of Health and Human Services and the American Society of Nephrology in April 2019. Prior to the announcement, Curion Research Corporation’s name was changed to US Kidney Research Corporation. They have a prototype built and plan to perform animal testing by October 2019.